两组药物治疗幽门螺杆菌感染的成本-效果分析  

Cost-effectiveness analysis of 2 therapeutic schemes for Helicobacter pylori infection

作　　者：骆松梅[1,2] 贺悦[1,2] 

机构地区：[1]浙江丽水市中心医院 [2]浙江省皮肤病防治研究所,丽水323000

出　　处：《海峡药学》2009年第12期220-222,共3页Strait Pharmaceutical Journal

摘　　要：目的评价两组药物治疗幽门螺杆菌感染的成本-效果。方法212例Hp感染患者随机分为A(奥美拉唑+克拉霉素+阿莫西林)、B(奥美拉唑+呋喃唑酮+阿莫西林)两组,分别观察其疗效和不良反应,并运用药物经济学成本-效果法进行分析。结果A、B组成本分别为162.12元、110.68元;Hp根除率分别为94.44%、94.23%;成本-效果比(C/E)分别为1.72、1.17;A组相对于B组的增量成本-效果比(△C/△E)为245。结论B组方案为较佳治疗方案。OBJECTIVE To evaluate the cost-effectiveness of 2 different therapeutic schemes for Helicobacter pylori infection.METHODS 212 cases of Hp infection were randomly divided into group A （Omeprazole＋Clarithromycin＋ Amoxicillin）and group B （Omeprazole＋Furazolidone＋Amoxicillin）.The therapeutic effects and the adverse drug reactions among groups were observed,and the data were subjected to cost-effectivenessanalysis in pharmacoeconomics.RESULTS The costs of group A and group B were 162.12 and 110.68 yuan RMB;the eradication rates of Hp were 94.44% and 94.23%;the ratio of costs results （C/E） were 1.72and 1.17;the ratio of the incremental costs results （C/E）was 245.CONCLUSIONS Among the 2 schemes,group B is the superior one.

关 键 词：幽门螺杆菌 药物治疗方案 成本-效果分析 

分 类 号：F404.4[经济管理—产业经济]